Related Experiment Video
Updated: Aug 1, 2025
12:25
Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
Published on: March 3, 2014
16.1K
Trends in Botulinum Toxin Use among Patients with Multiple Sclerosis: A Population-Based Study
Djamel Bensmail1,2, Pierre Karam3, Anne Forestier4
1Department of Physical and Rehabilitation Medicine, Raymond-Poincaré Teaching Hospital, APHP, Université Paris-Saclay, 92380 Garches, France.
Toxins
|April 27, 2023
Summary
This study analyzed botulinum toxin type A (BoNT-A) use in French multiple sclerosis (MS) patients from 2014-2020. It found varied treatment practices for spasticity and neurogenic detrusor overactivity, highlighting real-world data gaps.
Area of Science:
- Neurology
- Pharmacology
- Public Health
Background:
- Limited real-world data exists on botulinum toxin type A (BoNT-A) utilization in multiple sclerosis (MS) patients.
- Understanding treatment trends is crucial for optimizing patient care and resource allocation.
Purpose of the Study:
- To describe botulinum toxin type A (BoNT-A) treatment trends in French multiple sclerosis (MS) patients between 2014 and 2020.
- To analyze the utilization patterns of BoNT-A for MS-related spasticity and neurogenic detrusor overactivity (NDO).
Main Methods:
- Nationwide, population-based, retrospective cohort study utilizing the French National Hospital Discharge Database (PMSI).
- Inclusion of 105,206 patients coded with MS, identifying those receiving BoNT-A for striated muscle (spasticity) and/or detrusor smooth muscle (NDO).
Main Results:
- 8.0% of MS patients received BoNT-A for spasticity, with 52.9% receiving ≥3 injections (61.9% every 3-6 months).
- 2.8% received BoNT-A for NDO (mean 4.7 injections/patient, 60.0% every 5-8 months).
- 0.6% received BoNT-A for both conditions.
Conclusions:
- Significant variation in BoNT-A treatment practices observed in MS patients in France (2014-2020).
- The study provides essential real-world data on BoNT-A use for spasticity and NDO in MS.
- Further research is needed to standardize treatment protocols and improve outcomes.
More Related Videos
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
715
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
715
01:31Skeletal Muscle Relaxants: Therapeutic Uses
527
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
527
01:20Myasthenia Gravis: Overview and Treatment
1.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.7K
01:21Skeletal Muscle Relaxants: Adverse Effects
409
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
409
01:28Classification of Skeletal Muscle Relaxants
2.5K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.5K
01:24Centrally Acting Muscle Relaxants: Therapeutic Uses
758
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
758